The aim of the API-CAT trial was to assess whether the lower dose of apixaban was comparable to the full dose in preventing VTE recurrence in patients with active cancer who had completed at least ...

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at ...

Extended treatment with low-dose apixaban was noninferior to a full dose for preventing cancer-related VTE. Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant ... a 1:1 ratio to receive oral apixaban at a reduced (2.5 ...

the full-dose group) of apixaban for an additional 12 months. Neither patients nor their doctors knew which dose patients were receiving until the end of the trial. All deaths, suspected VTE ...

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status.

Summary Apixaban is an oral ... regimen in clinical trials without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...

“Best known as a trusted nausea remedy, ginger tea has a spicy and full-bodied flavour,” they said. “It contains the ...

A NEW study has shown that extended treatment with a reduced dose of apixaban can effectively prevent recurrent venous thromboembolism (VTE) in cancer patients while reducing the risk of bleeding.